Larvol Delta - Ulixertinib-in-Treating-Patients-With-Advanced-Solid-Tumors-NonHodgkin-Lymphoma-or-Histiocytic-Disorders-With-MAPK-Pathway-Mutations-A-Pediatric-MATCH-Treatment-Trial

ulixertinib (BVD-523) - BioMed Valley Discoveries

http://clinicaltrials.gov/ct2/show/NCT03698994

Apr 24, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next